About: http://webisa.webdatacommons.org/118879366

Property	Value
http://www.w3.org/1999/02/22-rdf-syntax-ns#type	http://www.w3.org/ns/prov#Entity
http://www.w3.org/ns/prov#value	The survival benefit associated with sorafenib remained significant after adjustment for ECOG performance status, tumor burden and other prognostic factors (hazard ratio 0.73, p = 0.004).
http://www.w3.org/ns/prov#wasQuotedFrom	chronicliverdisease.org